Needham analyst Michael Matson maintained a Hold rating on TransMedics Group (TMDX – Research Report) today. The company’s shares closed yesterday at $127.53.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Matson is an analyst with an average return of -6.5% and a 38.93% success rate. Matson covers the Healthcare sector, focusing on stocks such as TransMedics Group, Merit Medical Systems, and Establishment Labs Holdings.
Currently, the analyst consensus on TransMedics Group is a Moderate Buy with an average price target of $127.33.
Based on TransMedics Group’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $143.54 million and a net profit of $25.68 million. In comparison, last year the company earned a revenue of $96.85 million and had a net profit of $12.2 million
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year. Earlier this month, Anil P. Ranganath, the SVP, GC and Secretary of TMDX sold 686.00 shares for a total of $95,902.80.
Read More on TMDX:
- TransMedics price target raised to $150 from $130 at Oppenheimer
- TransMedics price target raised to $145 from $125 at Piper Sandler
- TransMedics Group Holds 2025 Annual Shareholders Meeting
- TransMedics Group: Buy Rating Affirmed Amid Strategic Positioning and FDA Approval Prospects
- Needham medtech & diagnostics analyst holds analyst/industry conference call